Complex Endometrial Hyperplasia With Atypia Clinical Trial
— feMMeOfficial title:
A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium
| Verified date | April 2023 |
| Source | Queensland Centre for Gynaecological Cancer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries. While highly effective, this surgery carries significant side effects for: - young women who still wish to have children and would lose fertility; and - women with one or more disorders (or diseases) in addition to the early stage endometrial cancer or endometrial hyperplasia with atypia and/or morbid obesity who are at risk for surgical complications making surgery unsafe. This study will access a new approach to the treatment of endometrial cancer to spare women of having to undergo major surgery that may be unwanted or unnecessary. Mirena is approved in Australia for contraception, to treat heavy bleeding, and to prevent thickening of the lining of the uterus (endometrial hyperplasia) during oestrogen replacement therapy (HRT). However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. This research project will test to see if Mirena is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. Metformin is approved in Australia to treat Diabetes. However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. Therefore, it is an experimental treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. This means that it must be tested to see if it is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. Weight loss interventions are feasible and safe, and already being implemented by gynaecologic oncologist to make women eligible for surgery. Weight loss of 7% body weight induces a large biological effect (for example reduces incidence of diabetes by 58%, and hypertension by 26%).
| Status | Active, not recruiting |
| Enrollment | 165 |
| Est. completion date | December 2023 |
| Est. primary completion date | October 3, 2022 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Females with a BMI > 30 kg/m2 wishing to retain fertility or females who are at high risk of surgical complications due to co-morbidities or obesity 2. Over 18 years of age at time of randomisation 3. Histologically confirmed complex endometrial hyperplasia with atypia or grade 1 endometrioid endometrial adenocarcinoma on a curette or endometrial biopsy 4. CT or MRI scan of pelvis, abdomen and chest (or chest X-Ray) suggesting the absence of extrauterine disease 5. Myometrial invasion on MRI of not more than 50%, for women with histologically confirmed Endometrial Cancer only (for women who are unable to fit into an MRI machine inclusion into trial is at investigators discretion) 6. No lymph vascular invasion on curetting or pipelle, if able to be assessed on sample 7. Serum CA125 = 30 U/mL 8. No hypersensitivity or contraindications for Mirena 9. Ability to comply with endometrial biopsies at specified intervals 10. Negative serum or urine pregnancy test in pre-menopausal women and women < 2 years after the onset of menopause 11. Creatinine < 150µmol/L (1.7 mg/dL) to be randomised into Mirena + Metformin arm (can still be eligible to be randomised to Mirena only or Mirena + Weight Loss, see section 5.4 Other Eligibility Criteria Considerations) Exclusion Criteria: 1. ECOG performance status > 3 2. Grade 1 endometrioid adenocarcinoma of the endometrium with myometrial invasion deeper than 50% on MRI or any patients with grade 2 or grade 3 endometrioid adenocarcinoma 3. Histological (cell) type other than endometrioid adenocarcinoma (sarcomas or high risk endometrial e.g. papillary serous, clear cell) 4. Pregnant or planning to become pregnant during trial period 5. Has had prior treatment or undergoing current treatment for EAC or EHA 6. Patients with a history of pelvic or abdominal radiotherapy 7. Unwilling to have additional endometrial biopsies or curettes and unable to attend three monthly clinical assessments 8. Unable to provide informed consent 9. Unable or unwilling to complete questionnaires 10. Evidence of extrauterine spread on medical imaging 11. Congenital or acquired uterine anomaly which distorts the uterine cavity 12. Acute pelvic inflammatory disease 13. Conditions associated with increased susceptibility to infections with microorganisms (e.g., AIDS, leukaemia, IV drug abuse) according to the patients Medical History 14. Genital actinomycosis 15. Current other cancer, except low grade malignancies that do not require any systemic treatment or treatment to the pelvis 16. Breastfeeding mothers 17. Mirena inserted greater than 12 weeks before randomisation/enrolment 18. Previous use of Mirena within the last 5 years from randomisation/enrolment 19. Contraindications to both Metformin and weight loss |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Royal Adelaide Hospital | Adelaide | South Australia |
| Australia | The Wesley Hospital | Auchenflower | Queensland |
| Australia | Royal Brisbane and Women's Hospital | Brisbane | Queensland |
| Australia | Chris O'Brien Lifehouse | Camperdown | New South Wales |
| Australia | Royal Women's Hospital | Carlton | Victoria |
| Australia | Monash Medical Centre | Clayton | Victoria |
| Australia | Greenslopes Private Hospital | Greenslopes | Queensland |
| Australia | King Edward Memorial Hospital for Women | Perth | Western Australia |
| Australia | Mater Health Services, Brisbane | South Brisbane | Queensland |
| Australia | Mater Private Hospital | South Brisbane | Queensland |
| Australia | Gold Coast Hospital | Southport | Queensland |
| Australia | St John of God Hospital | Subiaco | Western Australia |
| Australia | Townsville Hospital | Townsville | Queensland |
| New Zealand | Auckland City Hospital | Auckland | |
| New Zealand | Middlemore Hospital | Auckland | |
| New Zealand | Christchurch Women's Hospital | Christchurch | |
| New Zealand | Wellington Hospital | Wellington |
| Lead Sponsor | Collaborator |
|---|---|
| Queensland Centre for Gynaecological Cancer | Queensland University of Technology, The University of Queensland |
Australia, New Zealand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Pathological complete response | 6 months | ||
| Secondary | Predict the response to treatment | To predict the response to treatment through blood and tissue molecular biomarkers and to increase our molecular understanding of the biological pathogenesis of "early" EAC. | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02335203 -
The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
|
Phase 2 |